TROV TrovaGene Inc.

$0.405 -1.7%

2,000,000 Shares Traded
2,782,818 Average Volume (last 30 days)

as of March 23, 2018 EST IEX Real-Time Price

Short Pain Metrics

Approximate Amount of Money Shorts Have Made on the Day: $28.91 thousand
If Intiated on the First, Shorts Have Realized a Year to Date Return of:-35.08%
If Intiated One Month Ago, Shorts Have Realized a Return of:-28.71%
If Initiated Five Days ago, Shorts Have Realized a Return of:-4.3%
Peer Potential Short Squeezes Near Real Time Screener
*Please note the actual returns of shorts could be different as they started from different points

Daily Indicators

Daily Short Pain Indicator [i] - Always Use Fundamentals on EverythingNeutral
200 Day Moving Average Indicator Bearish
50 Day Moving Average Indicator Bullish
52 Week High/Low Indicator Neutral

Short Stats

Short Percent to Float 7.73%
Short Interest4.13 million
Float53.39 million
Short Ratio1.72
Market Cap$22.78 million
Market Maker ActivityDaily Short Volume


Trovagene to Present at the 26th Annual Wall Street Investor Conference (PR Newswire)
TrovaGene up 21% on early results form PMC-075 study (SeekingAlpha)
Trovagene Announces First Patient Successfully Completes Cycle 1 of Treatment with PCM-075 in Combination with Low Dose Cytarabine (LDAC) in AML Trial (PR Newswire)
Your Daily Pharma Scoop: Clovis Q4 Results, Endocyte Update, Merrimack Doses First Patient In MM-121 Mid-Stage Study (SeekingAlpha)
TrovaGene beats by $0.07, beats on revenue (SeekingAlpha)
Trovagene Announces Fourth Quarter and Full-Year 2017 Results (PR Newswire)
Your Daily Pharma Scoop: A Look At Celldex, BeiGene Data, Axovant Announces Changes At Top (SeekingAlpha)
Trovagene Announces Activation of Two Additional Clinical Trial Sites to Conduct its Phase 1b/2 Study of PCM-075 in Patients with AML (PR Newswire)
Trovagene's PCM-075 shows encouraging action in preclinical testing; shares up 22% (SeekingAlpha)
Trovagene Presents Data Showing Synergy of PCM-075 in Combination with Zytiga® in Castration-Resistant Prostate Cancer Model at 2018 Genitourinary Cancers Symposium (PR Newswire)

Smart Money Sentiment

Institutional Ownership (Top 15 Funds) 17.5%

Earnings Stats

PE Ratio -0.89
Dividend Yield 0%
Peer EarningsEarnings Calendar


200 Day Moving Average $0.65
50 Day Moving Average $0.34
52 Week High $1.63
52 Week Low $0.24

Data provided for free by IEX. Questions? Read the FAQ